Marcus W Koch 1 2, Jop P Mostert 3, Jerry S Wolinsky 4, Fred D Lublin 5, Bernard Uitdehaag 6, Gary R Cutter 7 Affiliations expand PMID: 34433679   DOI: 10.1212/WNL.0000000000012690 Abstract Background: Clinical trials in…

 written by:  Mary Alissa Willis, MD  – MS Neurologist, Jackson, MS Int J MS Care (2021) 23 (4): iv. https://doi.org/10.7224/1537-2073-23.4.iv The World…

  by Ed Tobias | August 20, 2021 Now that a third COVID-19 vaccine shot has been approved in the U.S. for immunocompromised people,…

  BioNTech’s experimental non-inflammatory vaccine — designed to dampen the abnormal immune responses seen in multiple sclerosis (MS) against myelin — delayed…

  Topic:  Trusted Information Sources in the MS Advocacy Community…Dr Mitzi chats with Podcast host Jon Strum and patient advocacy…

 August 10, 2021 The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered…

  Some DMTs may reduce the effectiveness of the COVID-19 vaccines People taking certain DMTs (ocrelizumab, rituximab, ofatumumab, and possibly…

Dealing with Migraine   (for the MS Community and beyond) If you’ve ever experienced a migraine headache, you know all too…

 August 20, 2021        – Marco Meglio NeurologyLive, August 2021, Volume 4, Issue 4 The agent’s safety profile has been studied in…

August 3, 2021 –   Abby Reinhard  Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates…